NanoXplore Reports First Quarter 2023 Results and Unveils Its 5-year Strategic Plan

NanoXplore Inc. ("NanoXplore" or "the Corporation") (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, reported today financial results for the first quarter ended September 30, 2022, and unveiled its 5-year strategic plan.

All amounts in this press release are in Canadian dollars, unless otherwise stated.

Q1 HIGHLIGHTS STRATEGIC PLAN HIGHLIGHTS
• Revenues from customers grew 52% to $27.1 million vs Q1-2022
• For Q1-2023, Gross margin was 11.6%, an increase of 860 bps over Q1-2022, and Adjusted EBITDA* totaled -$2 million, an improvement of $1.8 million over Q1-2022
• Total liquidity of $49.1 million as at September 30, 2022, including cash and cash equivalents of $42.8 million
• Total long-term debt of $9 million as at September 30, 2022
• For financial year 2023, NanoXplore is guiding for $110 million in total revenues
• The Corporation intends to increase its capacity 5-fold to reach 20,000 ton/year in graphene and battery materials in 5 years
• The Corporation will expand its Sheet Molding Compound (SMC) forming capacity by investing in an additional 10m-lbs capacity to target the large, growing, and promising lightweighting materials market, using its proprietary GrapheneBlack SMC TM
• The Corporation will actively participate in the energy transition and sustainability megatrends

OVERVIEW

Soroush Nazarpour, President and Chief Executive Officer, stated: "Despite being in a tough macro-environment, we are satisfied with the performance of our business. Our revenues from customers grew 52% and our gross margin continues to expand on a year-on-year basis based on better graphene-enhanced products. Having said that, supply chain challenges reduced our total expected revenue of this quarter and company-wide wage increase that we applied on July 1st, reduced our gross margin. We anticipate to offset the negative impact of supply chain disruption and wage increase with higher graphene sales as our graphene commercialization efforts continues."

Pedro Azevedo, Chief Financial Officer, stated: "I am very excited to share our strategic plan for the next 5 years.  It is a targeted approach in the areas we see the best uses for Graphene and where they will create the most value for our shareholders. I am also very pleased with the progress we have made in our financial performance since last year.  Comparing to Q1-2022, we have made significant improvements to gross margins, improved EBITDA and cut operating cash consumption by over 40% while investing in graphene uses with our partners."

Results of operations may include certain unusual and other items which have been separately disclosed, where appropriate, in order to provide a clear assessment of the underlying Corporation results. In addition to IFRS measures, management uses non-IFRS measures in the Corporation's disclosures that it believes provide the most appropriate basis on which to evaluate the Corporation's results.


A. THREE-MONTH PERIOD


Revenues

Q1-2023 Q1-2022 Variation
$ $ $ %
Revenues from customers 27,147,167 17,830,017 9,317,150 52%
Other income 85,358 988,429 (903,071) (91%)
Total revenues 27,232,525 18,818,446 8,414,079 45%

Revenues from customers increased from $17,830,017 in Q1-2022 to $27,147,167 in Q1-2023. This increase is mainly due to a positive product mix including graphene enhanced products, the acquisition of Canuck in December 2021 and price increases offset by lower fluctuating tooling revenues.

Other income decreased from $988,429 in Q1-2022 to $85,358 in Q1-2023. The decrease is explained by the end of the CEWS program set up by the Canadian Federal government to help businesses deal with the COVID-19 pandemic. The Corporation received nil under this program during Q1-2023 compared to $798,641 in Q1-2022 as the program ended in October 2021.


Adjusted EBITDA*

The adjusted EBITDA improved from -$3,760,406 in Q1-2022 to -$1,977,032 in Q1-2023. The variation is explained as follows:

  • Gross margin on revenues from customers increased by $2,624,033 compared to last year due to higher sales as describe above, improved productivity and cost control; and
  • This was offset by higher administrative expenses (SG&A and R&D) of $736,229 mainly due additional headcounts and higher wages, including higher accrued variable compensation.


B. STRATEGIC PLAN


By leveraging its proven formula and to further extend its market-leading position, NanoXplore is announcing, as part of its strategic plan ("Plan"), a significant increase in its graphene and battery materials capacity, reaching 20,000 tons in 2027 from 4,000 tons currently which represents a five-fold increase. Additionally, as part of the Plan, NanoXplore will invest in a 10M-lbs Sheet Molding Compound (SMC) facility in order to capture the large and growing SMC market which targets lightweighting solutions. Following a long and extensive review of its operations, top-down market analysis, and commercialization potential, the strategic plan lays out a path to accelerated growth in 2026 and beyond.

Soroush Nazarpour, President and Chief Executive Officer, stated: "The new strategic plan lays out a path to accelerated growth in the next few years, following successful completion of our previous five-year strategy. Our strategy is to narrow the scope of our funnel and focus on the highest probability of success and high-volume graphene powder applications. Accordingly, we are announcing a significant increase in our graphene and battery materials production capacity."

The Corporation, in order to accomplish its capacity expansion target, will require an investment of $170 million over the next five years, which the investments will be contingent to certain commercial milestones. This growth investment program will be financed through a combination of cash on hand, grants, debt, and equity, if needed. The capital allocation strategy will have the goal of achieving maximum shareholder value creation. The focus will be on three large, growing, and attractive markets: battery materials, lightweighting composites, and specialty compounds. The investments are as follows:

Assets Capacity Addition Location Commissioning year Potential Annual Revenue
Graphene and Battery Materials 12,000 tons/year Montreal, QC 2025 $100 million
SMC 10M lbs/year Newton, NC 2025 $80 million
Graphene 4,000 tons/year HQ 2026 $40 million


C. OTHER


Additional information about the Corporation, including the Corporation's Management Discussion and Analysis for the three-month periods ended September 30, 2022 and 2021 ("MD&A") and the Corporation's consolidated financial statements for the three-month periods ended September 30, 2022 and 2021 (the "financial statements") can be found at www.nanoxplore.ca .

* Non-IFRS Measures

The financial statements and MD&A were prepared using results and financial information determined under IFRS. However, the Corporation considers certain non-IFRS financial measures as useful additional information in measuring the financial performance and condition of the Corporation. These measures, which the Corporation believes are widely used by investors, securities analysts and other interested parties in evaluating the Corporation's performance, do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other publicly traded companies, nor should they be construed as an alternative to financial measures determined in accordance with IFRS. Non-IFRS measures include "Adjusted EBITDA".

WEBCAST

NanoXplore will hold a webcast tomorrow, November 15, 2022, at 8:30 am EST to review its first quarter ended September 30, 2022, results. Soroush Nazarpour, CEO and President of NanoXplore, and Pedro Azevedo, Chief Financial Officer, will host the event. To access the webcast please click on the link https://edge.media-server.com/mmc/p/7j3xvu2s or you can access through our website in the Investors section under Events and Presentations. A replay of this event can be accessed via the above link or on our website. To access the 5-year strategic plan presentation, please visit the Investors section under Events and Presentation at www.nanoxplore.ca .

ABOUT NANOXPLORE

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in industrial markets. The Corporation provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities in Canada, the United States and Europe.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements and forward-looking information (together, "forward-looking statements") within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements, and subject to risks and uncertainties. All forward-looking statements are based on our beliefs as well as assumptions based on information available at the time the assumption was made and on management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors deemed appropriate in the circumstances. No assurance can be given that these assumptions and expectations will prove to be correct. Forward-looking statements are not facts, but only predications and can generally be identified by the use of statements that include phrases such as "anticipate", "believe", "continue", "could", "estimate", "foresee", "grow", "expect", "plan", "intend", "forecast", "future", "guidance", "may", "predict", "project", "should", "strategy", "target", "will" or similar expressions suggesting future outcomes.

Forward-looking information is not a guarantee of future performance and involves a number of risks and uncertainties. Such forward-looking information necessarily involves known and unknown risks and uncertainties, including the relevant assumptions and risks factors set out in NanoXplore's most recent annual management discussion and analysis filed on SEDAR at www.sedar.com, which may cause NanoXplore's actual results to differ materially from any projections of future results expressed or implied by such forward-looking information. These risks, uncertainties and other factors include, among others, the uncertain and unpredictable condition of global economy, notably as a consequence of the Covid-19 pandemic. Any forward-looking information is made as of the date hereof and, except as required by law, NanoXplore does not undertake any obligation to update or revise any forward–looking statement as a result of new information, subsequent events or otherwise.

Forward-looking statements reflect management's current beliefs, expectations and assumptions and are based on information currently available to management. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve known and unknown risks and uncertainties and other factors that could cause actual results to differ materially from those contemplated by such statements.

No securities regulatory authority has either approved or disapproved the contents of this press release.

For further information, please contact:

Martin Gagné
Director of Investor Relations
martin.gagne@nanoxplore.ca
Tel: 1 438 476 1927


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GRA:CA,NNXPF
The Conversation (0)
Sona Nanotech

Sona Nanotech


Keep reading...Show less
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024.

Details for the Company's presentation:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two presentations at the American Diabetes Association's 84 th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.

The presentations are:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

  • Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb
  • CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk of death by 50%
  • FDA has given CEL-SCI the go-ahead to commence a confirmatory Registration Study for Multikine for the target population in head and neck cancer
  • Dr. Selvaggi will be supporting CEL-SCI to bring Multikine to patients through a confirmatory registrational path that has been agreed with regulatory authorities and that has a potential for cure

CEL-SCI Corporation (NYSE American: CVM) today announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor. Dr. Selvaggi joins CEL-SCI as the Company recently received its go-ahead from the U.S. Food and Drug Administration (FDA) for its confirmatory Registration Study of Multikine* in the treatment of head and neck cancer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606671425/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice

Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

  • Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues
  • First manufacturing services contract signed with Secretome Therapeutics

Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the launch of its contract development and manufacturing business at the Company's 15,000 square feet state-of-the-art Good Manufacturing Practice (GMP) facility. This facility contains 3,000 square feet of cleanroom space, including eight ISO 7 cleanrooms and ancillary areas, as well as 1,150 square feet of process development, quality control and warehousing space. The Company also announced the initiation of work under its first manufacturing services contract with Secretome Therapeutics a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×